NEWS & BLOG
Stay up to date with the latest news and updates from KCNQ2 Cure.
The KCNQ2 Cure Alliance publishes KCNQ2 Connections, our newsletter that will keep you up to date on highlighted blogs and news.
If you're looking to stay connected to KCNQ2 research and the KCNQ2 community, you've come to the right place. Our newsletter will keep you in the loop on:
- KCNQ2 Research – highlights new developments and clinical trial opportunities with links to helpful explanations on our website
- KCNQ2 Resources – new downloads, webinars, and more, so you won't miss any opportunities to stay informed and inspired
- Event Updates on our conference, events, and other chances to tap into the KCNQ2 community
Whether you’re a parent, friend, or researcher, we’ll keep you up to date with helpful information.
KCNQ2 Awareness Why We Recognize It in March
Channeling Hope: Why We Recognize KCNQ2 Awareness in March Each year in early March, our global community recognizes KCNQ2 Awareness Day on March 2 as part of KCNQ2 Awareness Week.…
Supporting Research for KCNQ2-Related Disorders
The KCNQ2 Biorepository Through our partnership with COMBINEDBrain, the KCNQ2 Cure Alliance has started to generate a collection of biological samples, called a biorepository. Different types of biological materials have…
Interested in Learning More About Gene Therapies?
KCNQ2 and Gene Therapy As genomics technologies continue to advance, so too has the potential of personalized treatments, including interventions that target specific genes. Because we know that variants in…
Expanded Access of Kv7.2 Channel Activators
Kv7.2 Channel Activators In many cases, KCNQ2-DEE is caused by reduced Kv7.2 potassium channel activity. Because of this, therapeutics that boost the activity of these channels are likely to be…
Praxis EMERALD Clinical Trial
KCNQ2 Cure hosted a webinar for the KCNQ2 community featuring a discussion with Praxis Precision Medicines. Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for disorders…
Reflections from the American Epilepsy Society Meeting 2025
Earlier this month, KCNQ2 Cure Alliance members attended the American Epilepsy Society (AES) meeting in Atlanta, Georgia. Our goal was to connect with scientists, clinicians, and industry partners to learn…
Promising Results from EMBOLD Study: What this Means for the KCNQ2 Community
KCNQ2 Cure Alliance attended the American Epilepsy Society (AES) meeting this week. One of the biggest pieces of news shared was positive results from a clinical trial testing a new…
Reflections from the 2025 KCNQ2 Cure Summit in Philadelphia
From September 26th to 28th, 162 members of the KCNQ2 community came together in Philadelphia for our 8th Family and Professional Summit. Attendees traveled from 22 states and six countries,…
Building Momentum: Insights from the KCNQ2 Research Roundtable
At this year’s KCNQ2 Cure Alliance Family and Professional Summit, Drs. Brooke Babineau and Alfred George brought together leaders from the scientific, clinical, and patient advocacy communities for a Research…
The Power of a CRID for Every KCNQ2 Family
Living with KCNQ2-related disorders means navigating a world of challenges-seizures, developmental hurdles, motor difficulties, behavioral complexities, and more. For those of us in the KCNQ2 community, the urgency for better…
Connecting Science and Community: Dr. Brooke Babineau Charts KCA’s Research Path as New Scientific Director
Hi! I’m Brooke Babineau, the new Scientific Director for the KCNQ2 Cure Alliance (KCA). I’m honored to join this devoted community and support a mission that empowers families through education,…
Reflections from the Rare As One Meeting
Reflections from the Rare As One Meeting: A Joint Message from Our Executive and Scientific Directors We recently returned from an invigorating three-day convening of the Chan Zuckerberg Initiative’s Rare…